Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)Xiuning Le, Mark A. Socinski, Julie R. Brahmer et al.|Cancer Research|2021Cited by 9